drugset / Trial / NCT02878694
Treatment of Ptosis to Muscular Dystrophy Oculopharyngeal by Myoblast Autologous Graft
Phase 2/3
Terminated
1 enrolled
University Hospital, Caen
Centre Hospitalier Universitaire, Amiens · collabGroupe Hospitalier Pitie-Salpetriere · collabRennes University Hospital · collabUniversity Hospital, Brest · collabUniversity Hospital, Lille · collabUniversity Hospital, Rouen · collab
NaSingle-groupOpen-labelTreatment
Summary
Interventional , multicenter , comparative study. One eye receiving the cells and the contralateral eye as a negative control . If effectiveness following review of the primary endpoint and the advice of an independent expert committee , the experimental treatment will be offered to the patient to the contralateral eyelid. Objective is to restore muscle function levator muscle of the upper eyelid by providing a registry of autologous myoblasts from a non- clinically affected muscle .
Timeline
- Start
- 2019-11-14
- Primary completion
- 2020-10-09
- Completion
- 2020-10-09
Outcome
Outcome not reported
Stopped (Enrollment): “insufficient recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | autologous myoblasts | Cell therapy | 30 cells | Intramuscular |